Nivolumab with AVD versus BEACOPP-like treatment for advanced Hodgkin lymphoma
Compares nivolumab then AVD against BEACOPP-like treatment in advanced classical Hodgkin lymphoma.
Plain-language title generated from the registry record
Registry title: Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL
Key facts
- Where
- Moscow and Saint Petersburg, RussiaSee the 3 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07234487, who can take part
Where in Russia
- A.N.Bakulev Center for cardiovascular surgery of the Russian Ministry of HealthMoscow, RussiaTaking people
- National Medical and Surgical Center named after N.I. PirogovMoscow, RussiaTaking people
- St. Petersburg State Pavlov Medical UniversitySaint Petersburg, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- St. Petersburg State Pavlov Medical University
- Trial code
- NCT07234487
- Record updated
- 1 April 2026
- Original description
Patients in this prospective multicenter phase II study will be randomized between two first-line therapy strategies for advanced stages of cHL. In the Nivo-AVD cohort, patients will receive 2 cycles of nivolumab monotherapy followed by a switch to Nivo-AVD combination therapy (total of 6 cycles); in the Standard cohort, patients will receive therapy according to current clinical guidelines in Russian Federation for first-line therapy of cHL, which include starting first-line therapy with 2 cycles of BEACOPP-like regimens and, after assessing response after 2 courses, switching to A(B)VD or continuing with BEACOPP-like regimensRead full original descriptionShow less
Randomized Study Comparing AVD Combined With Fixed-Dose Nivolumab Versus PET-Adapted BEACOPP-like Regimen as First-Line Treatment in Advanced Classical Hodgkin Lymphoma
Patients in this prospective multicenter phase II study will be randomized between two first-line therapy strategies for advanced stages of cHL. In the Nivo-AVD cohort, patients will receive 2 cycles of nivolumab monotherapy followed by a switch to Nivo-AVD combination therapy (total of 6 cycles); in the Standard cohort, patients will receive therapy according to current clinical guidelines in Russian Federation for first-line therapy of cHL, which include starting first-line therapy with 2 cycles of BEACOPP-like regimens and, after assessing response after 2 courses, switching to A(B)VD or continuing with BEACOPP-like regimens
Inclusion: Patients with newly diagnosed histologically confirmed stage IIB, III or IV classical hodgkin lymphoma who have not previously received specific therapy; Patients with evidence of lesion extent assessed by whole-body PET/CT; Patients aged 18-60 years; ECOG 0-2; Use of highly effective contraceptive methods from the moment of signing the informed consent form, throughout the study and within 6 months after receiving the last dose of the drug.
Exclusion: Active or prior documented autoimmune disease requiring systemic treatment; Simultaneous use of drugs or medical devices studied in other clinical trials; Respiratory failure > grade 1 at the time of enrollment; Uncontrolled bacterial or fungal infection at the time of enrollment; Hypersensitivity or allergy to study drugs; Severe organ failure: creatinine > 2 norms; alanine aminotransferase, aspartate aminotransferase > 5 norms; bilirubin> 1.5 norms; Requirement for vasopressor support at the time of enrollment; Pregnancy, breastfeeding, planning pregnancy or parenthood during the study period; Somatic or mental pathology that does not allow to perform research procedures, including the signing of informed consent.